Document Type

Working Paper

Date of this Version

2018

Advisor

Abby Alpert

Abstract

Global Health Technology Assessment (HTA) bodies vary in their scope and approach in Cost Effective Analyses (CEA) evaluating the clinical and economic efficacy of a proposed therapeutic against established metrics. This study characterized specific CEA approaches of various countries across standardized development indices and tested conditions of regression correlation against respective country health outcomes of interest. Additionally, we validate the existence of implicit and explicit values in country willingness-to-pay (WTP) thresholds and its statistically significance with country health expenditure and quality of care. Our multivariate regression models show that while CEA characteristics vary across countries, ultimate health outcomes are not dictated by CEA approach factors but rather in the broader context of country GDPPC development.

Keywords

Comparative Effectiveness Research, Pharmacoeconomics, Health Technology Assessment, cost-effective analysis, outcomes research

Share

COinS
 

Date Posted:11 September 2018

 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.